DonCorleone77
Posted - 2 months ago
$MRK $ESALY Merck, Eisai announce results from interim analysis of Phase 3 LEAP-012 trial Merck (MRK) and Eisai (ESAIY) announced results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with transarterial chemoembolization compared to TACE alone for the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma. These late-breaking data were presented for the first time during a Presidential Symposium at the European Society for Medical Oncology Congress 2024. After a median follow-up of 25.6 months, KEYTRUDA plus LENVIMA in combination with TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, reducing the risk of disease progression or death by 34% compared to TACE alone. Median PFS was 14.6 months for the KEYTRUDA plus LENVIMA-based regimen versus 10.0 months for TACE alone. At this analysis, a trend toward improvement in overall survival, the trial's other primary endpoint, was observed for the KEYTRUDA plus LENVIMA-based regimen versus TACE alone; the OS data are not mature and did not reach statistical significance at the time of this interim analysis. The trial is continuing, and follow-up of OS is ongoing. The safety profile of the KEYTRUDA plus LENVIMA-based regimen was consistent with that observed in previously reported studies evaluating the combination. Treatment was administered to 237 patients receiving the KEYTRUDA plus LENVIMA-based regimen and 241 patients receiving TACE alone. Treatment-related adverse events occurred in 98.7% of patients receiving KEYTRUDA plus LENVIMA in combination with TACE versus 84.6% of patients receiving TACE alone and led to the discontinuation of both study drugs in 8.4% versus 1.2% of patients, respectively. Serious adverse events were observed in 33.3% of patients receiving KEYTRUDA plus LENVIMA in combination with TACE versus 12.4% of patients receiving TACE alone. Grade 3 or 4 TRAEs occurred in 71.3% of patients receiving KEYTRUDA plus LENVIMA in combination with TACE versus 31.1% for TACE alone, and TRAEs led to death in 1.7% versus 0.4% of patients, respectively. LENVIMA monotherapy is approved for the treatment of patients with unresectable HCC in more than 80 countries, including in the U.S., Europe, China and Japan. KEYTRUDA is approved as a monotherapy for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen in the U.S. and as a monotherapy for the treatment of patients with HCC who have been previously treated with sorafenib or oxaliplatin-containing chemotherapy in China.
SigmundOoze
Posted - 08/23/24
$ESALY $BRCTF finally- something good moving these stocks...
https://www.bioarctic.com/en/leqembi-lecanemab-authorized-for-early-alzheimers-disease-in-great-britain/
ShareBusters
Posted - 08/22/24
$ESALY why is this showing $61.51, and WeBull and trading 212 is showing $10.69????
TStocksDollaz
Posted - 3 months ago
$SXTP has anyone mentioned the company we’re working with has a 10 billion dollar market cap!!!!! $ESALY https://www.investing.com/news/company-news/sxtp-stock-hits-52week-high-at-216-amid-robust-growth-93CH-3566900
Bob_C
Posted - 07/26/24
$SAVA - Breaking news. The EMA knows! $ESALY $BIIB - EMA CHMP issues negative opinion on the Alzheimer's drug lecanemab. The only negative drug opinion during their meeting!
"The committee considered that the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine, in particular the frequent occurrence of amyloid-related imaging abnormalities (ARIA), involving swelling and potential bleedings in the brain of patients who received Leqembi."
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024#:~:text=Negative%20opinion%20for%20one%20medicine,the%20treatment%20of%20Alzheimer%27s%20disease
Athenis
Posted - 5 months ago
$LLY $BIIB $ESALY Alzheimer's drug with the highest potential
TMC_2d_moon
Posted - 5 months ago
$ESALY would you gave us a strong indication as to your intent of interest to $ALLR. we would love to hear this from you. THANK YOU
ohyesarooni
Posted - 5 months ago
$ESALY Hey are you buying $ALLR in the next 75 days or so? have you heard any rumors?
DonCorleone77
Posted - 05/28/24
$BIIB $ESALY Biogen reports Leqembi approved for treatment of Alzheimer's in South Korea On May 27, Eisai (ESAIY) and Biogen (BIIB) announced that the Ministry of Food and Drug Safety, or MFDS, in South Korea has approved humanized anti-soluble aggregated amyloid-beta monoclonal antibody "Leqembi," or lecanemab, for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease, or AD, or mild AD. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In South Korea, Eisai Korea Inc. will distribute the product and conduct information provision activities.
celebratelife
Posted - 05/23/24
$CGTX Potential! Eisai's $ESALY Leqembi's price is $26k/year. At cost of $5 billion per year for healthcare system. We know margin on drugs is substantial. I haven't done a proper analysis but just for Alzheimer's CT-1812 should be valued at a couple of billion dollars or more (with positive data). Add the other indications the company is running trials for. A $5 billion market cap is not out of the question in my view. That's around $120 per share. Big Pharma knows this so CGTX will get taken out, which is Lisa's plan anyway, for I'm guessing, north of $40 a share.
Tank80
Posted - 05/19/24
$ALLR $ESALY MC 12B why not raise 1B and buy all of Allarity
KimberleyAnn
Posted - 6 months ago
$ESALY $ALLR @Tank80 did you notice the sp price and no news.
DonCorleone77
Posted - 10 months ago
$BIIB $ESALY Biogen, Eisai report Leqembi approved in China for Alzheimer's treatment Eisai Co. (ESALY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody "LEQEMBI" has been approved in China as a treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia. Preparations for launch within the second quarter of Eisai's FY 2024, July 1 - September 30, 2024, are underway, the companies stated.
TrendyChart
Posted - 10/26/23
Upcoming Earnings Report: $ESALY Eisai Co Ltd ADR will be reporting on 11/06/2023 at 3:00AM | Will earnings surpass or fall short of projections?
hurleyburly
Posted - 1 year ago
@HWtrying not so sure it's a two way race between $LLY and $ESALY anymore. Check out this story from last night's news on Alzheimers and NKGEN who is going public thru $GFOR https://pix11.com/video/experimental-alzheimers-treatments-showing-promise/8997554/
TangoToEvora
Posted - 07/24/23
$ESALY wow, what happened. +300%?
money01
Posted - 1 year ago
$ESALY no movement on this one?
money01
Posted - 1 year ago
$ESALY $BIIB seems to be reaping the benefits of Lecanemab...
money01
Posted - 1 year ago
$ESALY even better breakdown from Zack Bristow at seeking alpha. ...."The medication costs ~$26,500 annually, meaning patients would be forking out a maximum of $5,300 per year [at 80% reimbursement, or $441 per month] if not 100% covered"
money01
Posted - 1 year ago
$ESALY administered thru biweekly infusions ....there are 26 ( bi weeks/ yr ) so costs $1000/ mo. ...factor in insurance & medicare coverage....me thinks it's affordable to keep Grandma & Pa sharp. 😆
Lanai_Chris
Posted - 1 year ago
$ESALY google the details of the drug. It’s >$26k a year. Most people won’t have the resources to spend that amount on a prescription. 😢
money01
Posted - 1 year ago
$ESALY need to see some sales numbers...
MOONPYE2008
Posted - 1 year ago
$ESALY is anyone buying this? Curious that
money01
Posted - 1 year ago
$ESALY do they have any sales numbers yet?
Fast_Eddie_Felson
Posted - 1 year ago
$ESALY is this even going to move tomorrow or is BIIB going to see the action? Price action here is horrendous
DonCorleone77
Posted - 1 year ago
$BIIB $ESALY Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi The Food and Drug Administration converted Biogen (BIIB) and Eisai's (ESALY) Leqembi, indicated to treat adult patients with Alzheimer's Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit. Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer's disease, the agency said in a statement. The drug works by reducing amyloid plaques that form in the brain, a defining pathophysiological feature of the disease, it added. Leqembi was approved in January under the accelerated approval pathway.
marginalb
Posted - 1 year ago
$BIIB $ESALY which one to buy ?
marginalb
Posted - 1 year ago
$ESALY is this the approval $SPY ?
moneybags4ever
Posted - 1 year ago
$ESALY why does this company have two different ticker symbols..: ESAIY.. idk which one to buy
